Literature DB >> 19801833

A possible mechanism underlying an antidepressive-like effect of Kososan, a Kampo medicine, via the hypothalamic orexinergic system in the stress-induced depression-like model mice.

Naoki Ito1, Takeshi Yabe, Takayuki Nagai, Tetsuro Oikawa, Haruki Yamada, Toshihiko Hanawa.   

Abstract

Kososan, a Kampo (Japanese herbal) medicine, has an antidepressive-like effect in behavioral animal models of depression and has been used clinically for the improvement of depressive mood. However, mechanism(s) underlying the antidepressive-like effect of kososan remain unknown. Previous studies showed that orexin-A (OX-A), a neuropeptide that is involved in feeding and arousal, exhibits an antidepressive-like property via hippocampal cell proliferation. Here, we used immunohistochemical analysis with bromodeoxyuridine (BrdU), a marker of proliferating cells, to investigate the effect of long-term treatment with kososan on the orexinergic system and on hippocampal cell proliferation. Oral administration of kososan (1.0 g/kg) or milnacipran (60 mg/kg), a serotonin and noradrenaline reuptake inhibitor, for 28 d led to an antidepressive-like effect in the stress-induced depression-like model mice and reversed the stress-induced decrease in the number of OX-A-positive cells in the lateral hypothalamic area. In addition, both kososan and milnacipran alleviated the stress-induced decrease in the number of BrdU-positive cells in the hippocampal dentate gyrus. Moreover, the antidepressive-like effect and the increase in cell proliferation and in the number of neuropeptide Y (NPY, which is closely associated with orexinergic system)-positive cells in the dentate gyrus induced by kososan were blocked by treatment with SB-334867, an orexin receptor 1 antagonist. These results suggest that kososan exerts an antidepressive-like effect via the improvement of the stress-induced decrease in hippocampal cell proliferation and that the mechanism underlying the antidepressive-like effect of kososan, but not of milnacipran, may be associated with the regulation of orexinergic and/or NPYergic transmission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801833     DOI: 10.1248/bpb.32.1716

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  14 in total

Review 1.  Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.

Authors:  Mathieu Nollet; Samuel Leman
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

2.  Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.

Authors:  Clarissa D Staton; Jazmine D W Yaeger; Delan Khalid; Fadi Haroun; Belissa S Fernandez; Jessica S Fernandez; Bali K Summers; Tangi R Summers; Monica Sathyanesan; Samuel S Newton; Cliff H Summers
Journal:  Neuropharmacology       Date:  2018-09-18       Impact factor: 5.250

3.  Hcrtr1 and 2 signaling differentially regulates depression-like behaviors.

Authors:  Michael M Scott; Jacob N Marcus; Ami Pettersen; Shari G Birnbaum; Takatoshi Mochizuki; Thomas E Scammell; Eric J Nestler; Joel K Elmquist; Michael Lutter
Journal:  Behav Brain Res       Date:  2011-03-04       Impact factor: 3.332

4.  Antidepressant-like behavior in brain-specific angiogenesis inhibitor 2-deficient mice.

Authors:  Daisuke Okajima; Gen Kudo; Hiroshi Yokota
Journal:  J Physiol Sci       Date:  2010-11-27       Impact factor: 2.781

5.  Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.

Authors:  Mathieu Nollet; Philippe Gaillard; Arnaud Tanti; Virginie Girault; Catherine Belzung; Samuel Leman
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

6.  Orexinergic signaling mediates light-induced neuronal activation in the dorsal raphe nucleus.

Authors:  W Adidharma; G Leach; L Yan
Journal:  Neuroscience       Date:  2012-06-16       Impact factor: 3.590

7.  Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.

Authors:  S P Deats; W Adidharma; J S Lonstein; L Yan
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

Review 8.  Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.

Authors:  Cliff H Summers; Jazmine D W Yaeger; Clarissa D Staton; David H Arendt; Tangi R Summers
Journal:  Brain Res       Date:  2018-12-24       Impact factor: 3.252

9.  CDH13 and HCRTR2 May Be Associated with Hypersomnia Symptom of Bipolar Depression: A Genome-Wide Functional Enrichment Pathway Analysis.

Authors:  Chul-Hyun Cho; Heon-Jeong Lee; Hyun Goo Woo; Ji-Hye Choi; Tiffany A Greenwood; John R Kelsoe
Journal:  Psychiatry Investig       Date:  2015-07-06       Impact factor: 2.505

10.  The review of innovative integration of Kampo medicine and Western medicine as personalized medicine at the first multidisciplinary pain center in Japan.

Authors:  Young-Chang P Arai; Hiromichi Yasui; Hideya Isai; Takashi Kawai; Makoto Nishihara; Jun Sato; Tatsunori Ikemoto; Sinsuke Inoue; Takahiro Ushida
Journal:  EPMA J       Date:  2014-06-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.